NICE gives draft thumbs-up to Novartis inhaler; Mylan earnings leap 35%;

@FiercePharma: Novartis puts off restart at Lincoln, Neb., plant... again. Fed-up CEO says no more predictions--Bloomberg. News | Follow @FiercePharma

> The U.K.'s National Institute for Health and Clinical Excellence made a draft recommendation in favor of Novartis' ($NVS) lung treatment Tobi Podhaler. Report

> Generics maker Mylan ($MYL) posted a 35% increase in third-quarter earnings on a double-digit sales increase to $1.81 billion. Report

> Abbott Laboratories ($ABT) said its ALK genetic test is now available in Europe to identify patients suitable for Pfizer's ($PFE) targeted lung cancer drug Xalkori. Report

> Pharma manufacturers don't have a great reputation online, a new survey found, but social media may help change that. Report

> The U.K.'s cost-effectiveness watchdog says medicine prices in the country are under control, with costs falling by 0.4% over the past year. Report

Medical Device News

 @FierceMedDev: Alere warned by FDA for cardio Dx quality shortfalls. Item | Follow @FierceMedDev

 @MarkHFierce: A Senate report blasts Medtronic for improperly shaping data regarding its Infuse bone graft, all to boost sales. Story | Follow @MarkHFierce

 @DamianFierce: 2012 was less than a banner year for med device and diagnostic IPOs. We take a look at the numbers: Report | Follow @DamianFierce

> J&J's Ethicon hit with Class I over stapler recall. News

> FDA chides St. Jude over CRM plant. Story

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: Swedish bioinformatics group grabs $840K to fuel growth, report says. More | Follow @FierceBiotech

 @JohnCFierce: Signs of life? Top 10 biotech IPOs. Special Report | Follow @JohnCFierce

 @RyanMFierce: GSK's SROne leads $35M round for Thrasos Therapeutics for PhII study of kidney injury treatment. Release | Follow @RyanMFierce

> Ex-Geron chief spearheads bid to revive mothballed stem cell studies. News

> Shire chief prepares to hand over reins to hand-picked successor. Story

> Profit plunge stokes M&A buzz as AstraZeneca chief vows to strike more deals. Report

@AlisonBFierce: U. of Texas at Austin researchers got $6.5M from Dept. of Defense to develop new vaccines for emerging health threats. More | Follow @AlisonBFierce

> Italy bans Novartis influenza vaccines. News

> CDC green-lights GSK's meningitis vaccine for at-risk infants. Item

> HIV antibody development discovery advances vaccine search. Story

> EMA: 'Insufficient' link between narcolepsy and GSK flu vaccine. Report

> Novavax reports positive avian flu vaccine results. Article

Pharma Manufacturing News

> DSM snags another project to feed Australian biologics plant. More

> Novartis CEO defends manufacturing lapses. Article

> FDA group argues for helping poor countries beef up oversight. Story

And Finally... Sun Pharma's Dilip Shanghvi jumped into the top 5 on Forbes' list of wealthiest Indians. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.